ClinicalTrials.Veeva

Menu

Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

LG Life Sciences logo

LG Life Sciences

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: LC28-0126
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01737424
LG-CYCL001

Details and patient eligibility

About

To investigate the safety, tolerability and pharmacokinetic characteristics of LC28-0126 in healthy male subjects

Enrollment

89 patients

Sex

Male

Ages

20 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male subjects between the ages of 20 and 45 years at screening.
  • Subjects with BMI between 18.0(inclusive) and 27.0 kg/m2 (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive)

Exclusion criteria

  • Participation in a clinical research study within the previous 2 months
  • Regular alcohol consumption >21 units per week.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

89 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: Placebo
LC28-0126
Experimental group
Description:
LC28-0126(IV)
Treatment:
Drug: LC28-0126

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems